Invokana

Invokana Campaign Details

Prices listed are the current retail value and may be higher or lower based on availability, size of budget, demand, volatility and additional filters.

  • Invokana lead
    Call for pricing
  • Invokana signed
    Call for pricing

Invokana Criteria

  • Took one or more of the following medications for diabetes
    • Canagliflozin
    • Invokana
    • Invokamet
    • Invokamet XR
    • Sulisent
    • Dapagliflozin
    • Farxiga
    • Xigduo XR
    • Empagliflozin
    • Jardiance
    • Glyxambi
    • Synjardy
    • Tofogliflozin
    • Apleway
    • Deberza
    • Steglatro
    • Stegluromet
    • Qtern
  • Suffered from any of the following injuries while on the medication
    • Genital infection
    • Necrotizing fasciitis
    • Fournier's gangrene
    • Gangrene
    • Ischemia
    • Necrosis
    • Diabetic foot syndrome
    • Recurring infections
    • Charcot foot
    • Chronic ulcers or sores
    • Amputation
    • Kidney failure
    • Chronic kidney disease
    • Ketoacidosis
    • Diabetic coma
  • No legal representation

Invokana Background Information

Products

Invokana, Invokamet, Farxiga, Glyxambi, Jardiance, Xigduo XR

MDL 2750 (Invokana)

District of New Jersey, U.S. District Judge Brian R. Martinotti

MDL 2776 (Farxiga)

Southern District of New York, U.S. District Judge Lorna G. Schofield

Manufacturers

Johnson & Johnson, Janssen Pharmaceuticals Inc., AstraZeneca, Boehringer Ingelheim

Issues/ injuries

Failed to warn patients and physicians of the increased risks of kidney failure, heart attacks, ketoacidosis and diabetic ketoacidosis (DKA), loss of bone density, and severe Urinary Tract Infections (UTIs) requiring hospitalization.

Timeline of Events

  • 5/15/15 – FDA puts out a safety announcement that SGLT2 inhibitors may lead to ketoacidosis.
  • 5/18/17 – FDA issues new Black Box warning in regards to increased risk of leg, foot, and toe amputations for Invokana, Invokamet, and Invkoamet XR
  • 6/08/17 – JAMA new study published in the New England Journal of Medicine shows that SGLT2 inhibitors appear to have double the risk for DKA when compared to DPP-4 inhibitors
  • 8/29/18 – FDA issues a black box warning that SGLT2 inhibitors have been linked to Fourier’s gangrene, a rare, serious “flesh-eating” infection around the genitals

CONTACT US

We welcome you to contact Mass Torts USA for more information
about our products and services.